Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA (Nasdaq: SOPH) is frequently featured in news coverage as a cloud-native healthcare technology and AI company focused on precision medicine. News about SOPHiA GENETICS often centers on its SOPHiA DDM™ Platform, an AI-powered analytics environment that analyzes complex genomic and multimodal data to generate real-time, actionable insights for hospitals, laboratories, and biopharma institutions.
On this news page, readers can follow company announcements related to financial results, platform usage, and strategic direction. Recent press releases have discussed quarterly and preliminary full-year financial performance, including revenue trends, analysis volumes on SOPHiA DDM™, and guidance updates, as well as commentary from management on growth, operating leverage, and non-IFRS metrics.
Another major category of SOPH news involves collaborations and partnerships. SOPHiA GENETICS regularly announces agreements with cancer centers, academic institutions, sequencing technology providers, and biopharma companies. Examples include collaborations to co-develop next-generation sequencing oncology tests, integrate MSK-IMPACT® and MSK-ACCESS® assays powered with SOPHiA DDM™ on external sequencing platforms, and expand access to liquid biopsy and companion diagnostics in specific markets such as Japan.
Product and technology updates also feature prominently. The company has announced the launch of SOPHiA DDM™ Digital Twins, an AI-powered research technology that creates virtual representations of patients to simulate potential outcomes in oncology. Additional news highlights include partnerships that integrate SOPHiA DDM™ with sequencing systems to create streamlined, end-to-end workflows for next-generation sequencing and precision oncology research.
Investors, clinicians, and researchers who follow SOPH news can use this page to track developments in AI-driven precision medicine, including new applications on the SOPHiA DDM™ Platform, expansions of its global customer network, and collaborations aimed at advancing cancer and rare disease research.
SOPHiA GENETICS (Nasdaq: SOPH) reported a 42% year-over-year revenue increase for 2021, totaling $40.5 million. In Q4 2021, revenue reached $10.9 million, up 40% from Q4 2020. The company expanded its customer base, growing total recurring platform customers to 382. Despite strong revenue growth, operating losses increased to $21 million in Q4 and $71.5 million for the full year. The company expects 2022 revenue of $51.5 million to $54 million, reflecting growth of 27% to 33% over 2021. Cash reserves were approximately $265 million as of December 31, 2021.
SOPHiA GENETICS (Nasdaq: SOPH) and REALM IDx announced a letter of intent to collaborate on the co-development of genomic applications aimed at enhancing cancer care. This partnership seeks to improve next-generation sequencing (NGS) research and leverage multimodal data to enhance patient outcomes. The companies plan to utilize Ambry Genetics' TumorNEXT-HRD assessments and Variant Assessment database alongside SOPHiA's cloud-based DDM platform. This collaboration may lead to improved diagnostics by integrating genomics, radiology, and pathology data.
SOPHiA GENETICS (Nasdaq: SOPH) has announced that SOFIVA GENOMICS, a leading genetic testing company in Taiwan, is the first institution in the Asia Pacific to adopt their HRD testing technology. This collaboration focuses on advanced HRD detection using deep learning via the SOPHiA DDM Platform, which enhances cancer research capabilities. The technology has shown to detect more HRR genes compared to alternatives, potentially benefiting 150,000 ovarian cancer patients annually in the region. This partnership aims to improve precision medicine and data ownership for SOFIVA GENOMICS.
SOPHiA GENETICS (Nasdaq: SOPH) has announced that CEO Dr. Jurgi Camblong will speak at the Barclays Global Healthcare Conference on March 16, 2022, at 11:15 a.m. ET. The event will be held at the Loews Miami Beach Hotel, Miami, FL. A live webcast of the session will be available on the investor relations section of the SOPHiA GENETICS website.
This healthcare technology company focuses on data-driven medicine, utilizing its SOPHiA DDM™ Platform to analyze complex data sets for over 790 global healthcare institutions.
SOPHiA GENETICS has launched the SOPHiA DDM HRD Solution, aimed at enhancing cancer research through precise molecular testing. This solution identifies homologous recombination deficiency (HRD) mutations and analyzes genomic instability in tumor samples. Collaborating with AstraZeneca, SOPHiA aims to increase in-house HRD testing across Europe, particularly for advanced ovarian cancer patients. The solution allows labs to retain data ownership while saving time and costs. This innovative approach could significantly improve health outcomes in oncology.
SOPHiA GENETICS (Nasdaq: SOPH) has entered into an agreement with Hiroshima University to enhance molecular profiling for blood cancer through next-generation sequencing (NGS). This initiative aims to integrate NGS testing into routine clinical diagnostics for myeloid neoplasms in Japan. The SOPHiA DDM Platform will facilitate the identification of druggable targets and improve diagnosis accuracy. The partnership aligns with previous collaborations, including a long-term agreement with Hitachi, to expand data-driven medicine in the Japanese healthcare landscape.
SOPHiA GENETICS (Nasdaq: SOPH) will announce its fourth quarter and full year 2021 financial results on March 15, 2022, prior to U.S. market opening. A conference call and webcast discussing these results and future outlook will take place at 8:30 a.m. ET. The company specializes in data-driven medicine, utilizing its SOPHiA DDM™ Platform to analyze multimodal data sets. The platform is deployed by approximately 790 healthcare institutions worldwide, reinforcing SOPHiA's position in the healthcare technology sector.
SOPHiA GENETICS (Nasdaq: SOPH) has announced an extension of its partnership with Institut Paoli Calmettes (IPC) to enhance automated testing for solid tumors, including lung, breast, and ovarian cancers. This collaboration, which started in 2016, focuses on optimizing cancer management through genomic profiling, thereby minimizing sequencing costs and reporting times. IPC, recognized for managing hereditary cancers and hematologic malignancies, employs 1,800 personnel dedicated to comprehensive cancer care. The partnership aims to improve diagnostic accuracy and treatment predictions for cancer patients.
SOPHiA GENETICS (Nasdaq: SOPH) appointed Ken Freedman as Chief Revenue Officer on January 26, 2022. Freedman brings over 25 years of experience in sales and marketing from his previous role as Executive VP of Sales at Naviga, where he successfully grew revenue streams in North America and Latin America. His expertise is expected to bolster SOPHiA's expansion plans following a successful IPO. CEO Jurgi Camblong emphasized Freedman's motivational leadership and belief in data-driven approaches to enhance patient outcomes.
SOPHiA GENETICS (NASDAQ: SOPH) announced significant progress in its DEEP-Lung-IV clinical study, with 12 sites across 5 countries participating. The study aims to identify predictive biomarkers for non-small cell lung cancer (NSCLC) immunotherapy responses, addressing the limitations of the current PD-L1 biomarker. The initiative targets enrollment of 4,000 patients, with over 2,000 expected from initial sites. CEO Dr. Jurgi Camblong expressed optimism about the study's momentum and its potential impact in clinical settings.